Oxford Biomedica (LON:OXB) Stock Price Passes Below 200-Day Moving Average – Here’s What Happened

Shares of Oxford Biomedica plc (LON:OXB) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 663.97 and traded as low as GBX 630. Oxford Biomedica shares last traded at GBX 648, with a volume of 353,135 shares.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft increased their price target on Oxford Biomedica from GBX 735 to GBX 800 and gave the stock a “buy” rating in a report on Friday, January 9th. Stifel Nicolaus reiterated a “buy” rating and set a GBX 950 target price on shares of Oxford Biomedica in a research report on Wednesday, March 11th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of GBX 663.67.

Oxford Biomedica Price Performance

The firm has a market capitalization of £783.25 million, a P/E ratio of -17.89 and a beta of 1.04. The business has a 50-day moving average of GBX 761.05 and a 200 day moving average of GBX 663.97. The company has a current ratio of 1.89, a quick ratio of 1.67 and a debt-to-equity ratio of 322.11.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.